August 2012
-
In addition to presenting several posters related to OINDP analysis, Melbourn Scientific will also be introducing a new Qualified Person (QP) services at the upcoming American Association of Pharmaceutical Scientists (AAPS) annual meeting. The 2011… Read more . . .
-
Submit 500 word poster abstract to info@powderflow2011.com by November 4. You must be registered for the event in order to have your abstract accepted. For instructions in Mandarin, see 粉体流 2011. See complete submission information. Read more . . .
-
First quarter sales of Hi-Tech Pharmacal’s fluticasone proprionate nasal spray rose from $11,700,000 in 2010 to $26,200,000 this year, the company has announced, continuing a rapid increase in sales since the product was introduced. First… Read more . . .
-
Freeman Technology has moved to a new, larger facility in the Tewkesbury Business Park in Gloucestershire, UK. The new building includes office, laboratory, and manufacturing areas; additional space for expansion is available. Freeman has been… Read more . . .
-
Contract drug developer Xcelience has added micro-dosing capacity for the manufacturing of clinical supplies for dry powder inhaler delivery systems. The addition of an MG Futura capsule filler, says the company, “improves upon production times,… Read more . . .
-
On September 5, a ceremony in Tehran marked the occasion as Iran officially phased out CFC-based metered dose inhalers (MDIs) in accordance with the Montreal Protocol, becoming the first country in the Asia-Pacific region to… Read more . . .
-
UK drug delivery device company Bespak, a division of Consort Medical, says that it will develop a nasal delivery device “for a major unnamed global pharmaceutical company.” The contract, Bespak’s first for a nasal device,… Read more . . .
-
A group of researchers funded by the Research Institute for Fragrance Materials (RIFM) have developed a new model for vapor deposition in the lung and have published their work in an article titled “Derivation of… Read more . . .
-
An editorial by Monica Kraft in the August 31 online version of the New England Journal of Medicine voices approval for a recent article in the journal describing a study of lebrikizumab treatment for asthma… Read more . . .
-
According to the FDA’s latest update on the ongoing acetylcysteine inhalation solution shortage, all of American Regent/Luitpold’s product is still on back order due to “manufacturing delays,” and the company is still unable to estimate… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland